You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

relapsed indolent lymphoma

Showing 1 - 25 of 9,273
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas Trial in Boston (Imprime PGG, Rituximab)

Completed
Has Results
  • Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 20, 2022

Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma Trial run by the NCI (Obinutuzumab, Venetoclax, Magrolimab)

Recruiting
  • Follicular Lymphoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

Patterns in People With Indolent Non-Hodgkin Lymphoma,Type of

Active, not recruiting
  • Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
  • Copanlisib (BAY80-6946)
  • Multiple Locations, Taiwan
    Many Locations
Jan 31, 2023

Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Houston (other,

Completed
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 31, 2023

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Indolent Non-hodgkin Lymphoma Trial in Shanghai (IBI376)

Active, not recruiting
  • Indolent Non-hodgkin Lymphoma
  • Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
Oct 3, 2022

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma Trial in Milano (intralesional rituximab, supplemental autologous

Completed
  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
  • intralesional rituximab
  • supplemental autologous serum
  • Milano, Italy
    Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte T
Aug 2, 2022

Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma Trial in Japan (ME-401)

Active, not recruiting
  • Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
  • Nagoya, Aichi, Japan
  • +5 more
Dec 10, 2021

Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
Mar 11, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Atlanta, Columbus (drug, biological,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • PI3K inhibitor BKM120
  • +3 more
  • Atlanta, Georgia
  • +1 more
Jun 27, 2022

Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma Trial in Minneapolis (Nicotinamide Expanded Haploidentical

Completed
  • Multiple Myeloma
  • +7 more
  • Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Nov 2, 2022

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma Trial in Columbus (drug, biological,

Active, not recruiting
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +9 more
  • BTK inhibitor PCI-32765
  • +5 more
  • Columbus, Ohio
    Ohio State University Medical Center
Jun 27, 2022

Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +11 more
  • Biopsy
  • +5 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Indolent B-Cell Non-Hodgkin Lymphoma Trial in Worldwide (BI1206)

Recruiting
  • Indolent B-Cell Non-Hodgkin Lymphoma
  • BI1206
  • Atlanta, Georgia
  • +8 more
Mar 1, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma Trial in

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Jan 20, 2023

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to DLBCL Trial

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +2 more
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 5, 2023

Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
  • +8 more
  • Biospecimen Collection
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Mar 8, 2023

Marginal Zone Lymphoma, Follicular Lymphoma, DLBCL Trial in China (Zanubrutinib, Rituximab)

Completed
Has Results
  • Marginal Zone Lymphoma
  • +2 more
  • Harbin, Heilongjiang, China
  • +3 more
Oct 26, 2021

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,

Suspended
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +23 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 23, 2022

Lymphoma Non-Hodgkin Trial in Japan (Copanlisib (BAY80-6946))

Completed
  • Lymphoma Non-Hodgkin
  • Copanlisib (BAY80-6946)
  • Nagoya, Aichi, Japan
  • +12 more
Feb 21, 2022

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022